Choose   Change
BGI Advancing Genomics Together
BGI Advancing Research
BGI Advancing Drug Discovery
BGI Advancing Healthcare
News
/by

International Sc2.0 Project On Track to Build World’s First Synthetic Yeast Genome

March 9th, 2017 – Shenzhen. A team from the international Synthetic Yeast Genome Project (Sc2.0 project) have announced the completion of the de novo redesign and synthesis of five more chromosomes of Saccharomyces cerevisiae; chromosomes II, V, VI, X and XII. The researchers also performed an in-depth, multi-dimensional analysis on the yeast strain, and confirmed that the phenotype of the synthetic yeast strain is consistent to that of the wild-type.
Spotlight
/by

Gene Expression Sequencing at Array Prices!

The higher cost of NGS has prevented routine adoption of RNA sequencing, until now. BGI is proud to introduce Gene Expression Sequencing Services, with all the benefits from NGS data, but at a cost that is comparable to that of microarrays.

Discover BGI’s Exome Sequencing Service

– 100 bp and 150bp Paired End sequencing options available
– Guaranteed ≥ 80% of bases with quality score of ≥Q30
– CAP compliant facility in Hong Kong
– US FDA 21 CFR Part 11 compliant processes

Events
/by

BGI will be at BioGenomics 2017

From February 21-23, you will be able to find us at The BioGenomics 2017 conference to be held in the Smithsonian’s National Museum of Natural History in Washington DC. BGI is a proud sponsor and co-organizer. Please come by to say hi and discuss your NGS project needs. We are looking forward to seeing you.

Don’t hesitate to contact us to request a quote or to talk more about your requirements and how we can support your needs.

About BGI

BGI was founded in 1999 as a nonprofit research organization. Over the years, BGI has grown into a multinational genomics company with significant global operations and a wide variety of next generation sequencing (NGS) services including whole genome sequencingexome sequencing and RNA sequencing. With more than 5,000 employees across the globe and R&D, manufacturing, and commercial operations around the world, BGI is committed to providing genomics solutions to address the research, pharmaceutical, and clinical markets while utilizing the power of NGS technology in order to improve human health and empower large-scale human, plant, and animal genomics research.

________________________________________________________________________________________

9

Offices

On 5

Continents

With over 5000

Employees

Copyright © BGI 2016